Diametric Capital, LP Lineage Cell Therapeutics, Inc. Transaction History

Diametric Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.2 - $1.53 $61,050 - $77,838	50,875 New	50,875 $76,000
Q2 2021 Aug 16, 2021	SELL	$2.17 - $3.0 $57,965 - $80,136	-26,712 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $47,280 - $82,807	26,712 New	26,712 $63,000
Q3 2020 Nov 13, 2020	SELL	$0.75 - $1.09 $17,675 - $25,688	-23,567 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $16,732 - $27,809	23,567 New	23,567 $21,000

135

106M

22.1K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $90M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.